Drug Database
TR

trastuzumab (HS 022 / HS022 / anruize)

✓ Approved

BioRay Pharmaceutical · ERBB2 · 单克隆抗体

什么是 trastuzumab?

trastuzumab 是一种单克隆抗体,由BioRay Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名HS 022, HS022, anruize
公司BioRay Pharmaceutical
药物类别单克隆抗体, 抗体
分子靶点ERBB2
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

trastuzumab 作用于 1 个分子靶点:

ERBB2erb-b2 receptor tyrosine kinase 2 (NEU, CD340)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

trastuzumab 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Gastric cancer✓ Approved

相关研究文献

PubMedEye (London, England)2026-11-19

Comprehensive evaluation of drug-related vision disorder risk in breast cancer patients: a global pharmacovigilance analysis.

Chen Heng H, Hou Ju J, Song Hui H, Ouyang Lihui L et al.

Breast cancer, the most common malignancy in women worldwide, has a high incidence and mortality rate, with treatments like chemotherapy and targeted therapies improving survival but causing ocular toxicity. In this study, we analysed potential risk signals for vision disorders in breast cancer patients using the FAERS from January 2020 to December 2024. Disproportionate analysis was performed to identify positive signals, with a reporting odds ratio (ROR). Multiplicative models were used to assess drug-drug interactions. Moreover, the time to onset of vision disorders was also evaluated. A total of 2402 cases of vision disorders occurring in breast cancer patients were included. The median onset time for vision disorders was 17.5 days (IQR: 2.5-84.5), with hospitalisation (19.9%) and disability (7.4%) as common outcomes. Among the top 20 most frequently used drugs, tamoxifen (ROR = 2.29, 95% CI: 1.68-3.13) and trastuzumab emtansine (ROR = 1.98, 95% CI: 1.49-2.64) showed the strongest associations with vision disorders. Combination therapy analysis identified positive interaction signals for ribociclib with most endocrine therapies. This study systematically evaluated potential risk signals for vision disorders associated with medication use in breast cancer patients. These findings may support clinical vigilance for potential ocular AEs but do not quantify treatment risk or establish causality.

PMID 43052412
阅读全文 →
PubMedCardio-oncology (London, England)2026-11-19

Assessment of the HFA-ICOS risk tool for predicting cancer therapy-related cardiac dysfunction: a prospective cohort study.

Guerra Enrique C EC, Aparicio-Ortiz Alexis D AD, Barac Ana A, Asch Federico M FM et al.

Anthracyclines and HER2-targeted breast cancer treatments can cause cancer therapy-related cardiac dysfunction (CTRCD). The Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) risk tool assesses this risk, but its accuracy remains uncertain. We aimed to (1) determine CTRCD incidence using the 2021 CTRCD definition in breast-cancer patients receiving doxorubicin and/or trastuzumab; (2) evaluate the HFA-ICOS risk proformas, and (3) assess the individual risk factors incorporated in the proformas. In this prospective study, 186 women with early-stage breast cancer were enrolled to undergo baseline and serial cardiac evaluations over 12 months. After exclusions, 177 patients were included for risk stratification using the Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) score. Baseline risk distribution was 67% low (n = 116), 28% moderate (n = 52), and 5% high (n = 9). During follow-up, 53 patients (28.6%) developed cancer therapy-related cardiac dysfunction (CTRCD), corresponding to an overall incidence rate of 0.266 events per person-year (95% CI 0.200-0.348). Incidence rates were 0.326, 0.145, and 0.248 in the low-, moderate-, and high-risk groups, respectively; pairwise 365-day restricted mean survival time (RMST) comparisons did not remain statistically significant after Holm adjustment (all adjusted p > = 0.124). In Cox models adjusted for treatment type, CTRCD risk did not differ significantly between the moderate- and high-risk groups compared with the low-risk group. The ordinal HFA-ICOS category showed poor discrimination for time to CTRCD (Harrell C-index 0.43, 95% CI 0.37-0.49). The HFA-ICOS proforma showed limited ability to stratify CTRCD risk in this cohort. These findings highlight limitations in current guideline-based risk models and the need for improved stratification strategies.

PMID 43053233
阅读全文 →
PubMedFrontiers in oncology2026-11-18

Case Report: Trastuzumab-deruxtecan as 11th line therapy in a metastasized ovarian clear cell carcinoma patient expressing HER2 1.

Wolfrum Angelika A, Ladurner Julia J, Abendstein Burghard B

Ovarian clear cell carcinoma (OCCC) is a rare histologic subtype of epithelial ovarian cancer, accounting for approximately 5%-10% of cases in Western populations. Compared with high-grade serous ovarian cancer, OCCC is characterized by lower sensitivity to conventional cytotoxic chemotherapy and consequently poor outcomes. Given the limited efficacy of standard systemic therapies, there is a considerable unmet need for novel treatment strategies in OCCC. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic class across several solid tumors. Among these agents, trastuzumab deruxtecan (TDXd) has demonstrated substantial clinical activity in HER2-expressing malignancies and has recently shown efficacy across multiple tumor types in the DESTINY-PanTumor02 trial, but with low evidence in OCCC. Here, we report a patient with heavily pretreated recurrent ovarian clear cell carcinoma who achieved a durable and clinically meaningful response to trastuzumab deruxtecan despite low HER2 expression (IHC 1+).

PMID 43047483
阅读全文 →
PubMedFrontiers in nuclear medicine2026-11-18

Automated cassette-based production, purification, and radiolabeling of [89Zr]Zr-DFO-trastuzumab.

Tesse Giuseppe G, Capasso Giuseppe G, Cazzola Emiliano E, Tolomeo Anna A et al.

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is an aggressive subtype of breast cancer in which accurate, non-invasive assessment of HER2 expression is critical for the stratification of patients and monitoring of treatment. Immuno-positron emission tomography using monoclonal antibodies radiolabeled with long-lived positron emitters, such as [89Zr]zirconium, enables whole-body visualization and quantification of HER2 expression. This study aimed to develop and validate a fully integrated, sequential, and automated cassette-based synthesis process for the production, purification, and radiolabeling of [89Zr]Zr-desferrioxamine (DFO)-trastuzumab for potential clinical application. In this study, [89Zr]zirconium was produced via cyclotron irradiation of sintered [89Y]yttrium solid targets, followed by purification using a hydroxamate-based solid-phase extraction (SPE) system. The resulting [89Zr]Zr(C2O4)2 was used to radiolabel trastuzumab preconjugated with the chelator DFO, and the final radiopharmaceutical was purified via PD-10 size-exclusion chromatography. The automated workflow integrated target dissolution, [89Zr]zirconium capture and elution, buffer adjustment, antibody radiolabeling, PD-10 purification, and sterile filtration within a single disposable cassette installed on an AllinOne synthesis module. The principal process parameters investigated were target dissolution time, acid concentration and washing volumes, [89Zr]zirconium elution conditions, reaction temperature, reaction time, antibody concentration, and starting activity. Preliminary manual radiolabeling experiments were performed at 37 °C to define the radiolabeling conditions, whereas the subsequent automated radiolabeling reaction was performed at 30 °C for 60 min. Radiochemical purity (RCP) and radiochemical yield (RCY) were evaluated via high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC). All steps were integrated into a single-use cassette installed on a commercial synthesis module to minimize manual handling. Target dissolution and SPE purification yielded [89Zr]Zr(C2O4)2 with an average recovery of approximately 90% and high radionuclidic purity. In preliminary manual experiments, radiolabeling yields of approximately 90% were obtained after 60 min. In contrast, four subsequent automated production runs using starting activities ranging from 37 to 185 MBq showed isolated radiochemical yields ranging from 65% to 78%. The HPLC radiochemical purity was 100% in all automated production runs, while TLC analysis of the final product showed 99%-100% radiochemical purity. Following PD-10 purification, the final product showed 99%-100% radiochemical purity in TLC and a pH of approximately 7. The automated cassette-based workflow demonstrated reproducible radiochemical purity and reduced direct operator handling of the radioactive material, while the lower isolated automated RCY indicated that activity recovery and fluidic transfer efficiency remain areas for further optimization. The developed cassette-based system demonstrated the feasibility of integrating [89Zr]zirconium target dissolution and purification with subsequent radiolabeling and purification of preconjugated DFO-trastuzumab in a single automated sequence. Although the overall automated RCY was lower than the labeling yields obtained in preliminary manual experiments, the consistently high RCP indicates that the main opportunity for further optimization lies in overall activity recovery and fluidic transfer efficiency rather than in the chemical purity of the final product. This process reduces direct operator handling of radioactive material and provides a standardized platform that may be further developed into a Good Manufacturing Practice-compliant production method for [89Zr]-labeled monoclonal antibodies.

PMID 43047657
阅读全文 →
PubMedBioconjugate chemistry2026-11-18

SuFEx-Enabled Tyrosine Specific Bioconjugation of Near-Infrared Fluorophores.

McKay Paula T PT, Nashawati Stefan S, Kodisana Mohan M, Aden Jude E JE et al.

Sulfur (VI) fluoride exchange (SuFEx) chemistry has been widely applied in small-molecule medicinal chemistry, but its translation to near-infrared (NIR) fluorophores and application to antibody labeling remain largely unexplored. Here, we report a general synthetic approach for the preparation of aryl sulfonyl fluoride-functionalized indolenines and their incorporation into heptamethine cyanine (Cy7) fluorophores. The strategy is compatible with a broad range of indolenine substrates bearing diverse electronic and solubilizing substituents, enabling the synthesis of a library of water-soluble, SuFEx-enabled Cy7 fluorophores. Using SAT-NIR-746-SF as a lead probe, we demonstrate that the aryl sulfonyl fluoride handle is stable under physiologically relevant conditions (t1/2 > 18 h at pH 7.4) and enables efficient antibody labeling (degree of labeling up to 6.1) under mild aqueous conditions. The degree of labeling can be systematically controlled by varying reaction pH, incubation time, and reagent stoichiometry. The strategy was successfully applied to therapeutic monoclonal antibodies, including trastuzumab, panitumumab, and cetuximab, and the resulting conjugates were stable under acidic, physiological, and serum conditions. Amino acid selectivity assays and tandem mass spectrometry-based proteomics of labeled trastuzumab confirmed modification exclusively at tyrosine residues, establishing the tyrosine-selective nature of this conjugation platform. SAT-NIR-746-SF-conjugated secondary antibodies provided specific labeling of phospho-histone H3 (H3S10P) in confocal immunofluorescence microscopy. These results establish SuFEx-enabled Cy7 fluorophores as a practical platform for tyrosine-selective antibody bioconjugation and demonstrate their utility in fluorescence imaging applications.

PMID 43046850
阅读全文 →
PubMedInternal medicine (Tokyo, Japan)2026-11-18

Cancer Genomic Medicine in Japan: Current Status and Future Perspectives.

Sasaki Rika R, Takeda Masayuki M

Cancer genomic medicine (CGM) encompasses the integration of tumor genomic information into clinical decision-making. In Japan, comprehensive genomic profiling (CGP) is an essential component of CGM, as it facilitates the identification of actionable alterations, clinical trial enrollment, and treatment selection. Following the initiation of national insurance coverage in 2019, Japan has established a nationwide CGM network. However, clinical implementation remains limited by institutional restrictions, such as delayed testing and insufficient access to matched therapies. Recent evidence from CGP-guided therapies and expanding tumor-agnostic approvals, including those for trastuzumab deruxtecan for human epidermal growth factor receptor 2 (HER2)- positive solid tumors and alectinib for anaplastic lymphoma kinase (ALK) fusion-positive solid tumors, underscores the growing therapeutic relevance of molecular profiling and is expected to further accelerate precision oncology. This review summarizes recent advances in CGM that enable treatment selection based on molecular alterations beyond conventional tumor type-based approaches and discusses future directions considering the current healthcare system and challenges in Japan.

PMID 43051904
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多trastuzumab